Biopharma M&A Deal Values Jump 101% to $37.7 Billion in Q1 2025

The biopharmaceutical industry saw a significant increase in mergers and acquisitions (M&As) during the first quarter of 2025. Deal values more than doubled, with a 101% surge compared to the previous quarter. Specifically, the total value of M&A deals reached $37.7 billion in Q1 2025. This is a considerable jump from the $18.8 billion recorded in the fourth quarter of 2024, according to data from GlobalData’s Pharmaceutical Intelligence Center Deals Database.

Newsflash | Powered by GeneOnline AI
Date: May 6, 2025

Related posts:

GLP-1 Weight Loss Drugs Might Cause Blindness Duke University Engineers Develop AI Platform to Target “Undruggable” Diseases Study Reveals Brain’s Role in Regulating Ear Sensitivity and Compensating for Hearing Loss February Roundup: Key Executive Changes in the Healthcare Sector

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後